At a glance
- Originator Agouron Pharmaceuticals
- Class Antineoplastics; Ribonucleotides; Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Oct 1997 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 08 Sep 1997 Preclinical development for Cancer in USA (Unknown route)